4D pharma announces three presentations at The Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020
4d Pharma PLC (DDDD.L) Topline Results for Blautix® phase II trial
Positive trends seen in primary efficacy endpoint of the study of overall response in both IBS-C and IBS-D subgroups